Biological potency evaluation and physicochemical characterization of unfractionated heparins;Avaliação biológica de potência e caracterização físico-química de heparinas não fracionadas

Revista Brasileira de Hematologia e Hemoterapia

Volumn 31, Issue 5, 2009, Pages 23-30

  Dalmora, Sérgio L ^a   Souto, Ricardo B ^a   Silva, Lucélia M ^a   Lana, Aline D ^a   Schutkoski, Renato ^a   Vaccari, Silvana F ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Activated partial thromboplastin time; Anti factor IIa; Anti factor Xa; Capillary electrophoresis; Protamine; Unfractionated heparins

Indexed keywords

EID: 77952649608     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-84842009005000074     Document Type: Article

References (24)

1. Boneu B. Low molecular weight heparins: are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis? Thromb Res. 2000;100(2):V113-V120.
2. Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs. 1990;40(4):498-530.
3. Brunton LB, Lazo JS, Parker KL (Eds.), Goodman & Gilmans the pharmacological basis of therapeutics, 11th ed., McGraw-Hill, New York, 2006.
4. Hirsh J, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1992;102(4 Suppl):337S-351S.
5. Di Nisio M, Middeldorp S, Büller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353(10):1028-1040.
6. Björk I, Lindahl U. Mechanism of the anticoagulant action of heparin. Mol Cell Biochem. 1982;48(3):161-182.
7. Guerrini M, Beccati D, Shriver Z, Naggi A, Viswanathan K, Bisio A, et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol. 2008;26 (6):669-675.
8. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008;358(23):2457-2467.
9. Zhang Z, Weïwer M, Li B, Kemp MM, Daman TH, Linhardt RJ. Oversulfated chondroitin sulfate: impact of a heparin impurity, associated with adverse clinical events, on low-molecular-weight heparin preparation. J Med Chem. 2008;51(18):5498-5501.
10. The United States Pharmacopeia. 31 edition. Rockville: The United States Pharmacopeial Convention, 2008.
11. European Pharmacopoeia. 6th edition. Strasbourg: Council of Europe, 2008.
12. Barrowcliffe TW. Heparin assays and standardization. In: Lane D. A, Lindahl U. (Ed). Heparin. London: Edward Arnold, 1988; 393-415.
13. Vaccari SF, Brum LJR, Masiero SMK, Fronza M, Dalmora SL. Avaliação comparativa da atividade biológica de heparinas não- fracionadas em produtos farmacêuticos. Rev. Bras. Hematol. Hemoter. 2003;25(2):103-110.
14. Ramasamy I, Kennedy J, Tan K. Capillary electrophoresis for characterization of low molecular weight heparins. Lab Hematol. 2003;9(2):64-66.
15. Beyer T, Diehl B, Randel G, Humpfer E, Schäfer H, Spraul M, et al. Quality assessment of unfractionated heparin using 1H nuclear magnetic resonance spectroscopy. J Pharm Biomed Anal. 2008; 48 (1):13-9.
16. British Pharmacopoeia, London: The Stationery Office, 2008.
17. Melo EI, Pereira MS, Cunha RS, Sá MP, Mourão PA. Controle de qualidade das preparações de heparinas disponíveis no Brasil: implicações na cirurgia cardiovascular. Rev Bras Cir Cardiovasc. 2008;23(2):169-74.
18. Patel RP, Narkowicz C, Hutchinson JP, Hilder EF, Jacobson GA. A simple capillary electrophoresis method for the rapid separation and determination of intact low molecular weight and unfractionated heparins. J Pharm Biomed Anal. 2008;46(1):30-5.
19. The United States Pharmacopeial Convention. Revision Bulletin. Rockville: June 18, 2008.
20. Farmacopéia Brasileira. 4 edição. São Paulo: Atheneu, 1988.
21. Dalmora SL, Assaf GS, Dalmora ME, Vaucher LC, Vaccari SF. Determinação da atividade anticoagulante da heparina. Rev Hosp Clin Fac Med Sao Paulo. 1991;46(2):59-62.
22. Dalmora SL, Júnior LB, Schmidt CA, Vaccari SF, Oliveira PR, Codevilla CF. Validation of the anti-factor Xa assay for the potency assessment of enoxaparin in pharmaceutical formulations. J AOAC Int. 2004;87(6):1305-08.
23. Dalmora SL, Junior LB, Vaccari SF, Fronza M, Renato de Oliveira P, Rolim CM. Validation of the anti-factor IIa assay and potency assessment of enoxaparin in pharmaceutical formulations. Farmaco. 2005;60(3):225-9.
24. Finney DJ, Statistical Methods in Biological Assay, Charle Griffin, London UK. 1978.